Phospho-IRF3 (S386) Antibody

What is IRF-3 and why is phosphorylation at S386 important?

IRF-3 (Interferon Regulatory Factor 3) is a critical transcription factor in the innate immune response pathway. Phosphorylation at Serine 386 represents a key regulatory event in IRF-3 activation. Studies by the Fujita lab demonstrated that phosphorylation site 1 (which includes Ser386 in human IRF-3) plays a pivotal role in IRF-3 activation, with S386 phosphorylation being directly detectable following viral infection using specific antibodies . This post-translational modification is essential for IRF-3 dimerization, as mutation of Ser386 abolishes this process . The phosphorylation event triggers a conformational change that allows IRF-3 to form stable dimers, translocate to the nucleus, and induce type I interferon production .

What techniques can Phospho-IRF3 (S386) antibodies be used for?

Phospho-IRF3 (S386) antibodies are versatile research tools applicable across multiple experimental techniques:

The HTRF (Homogeneous Time-Resolved Fluorescence) phospho-IRF3 assay represents an advanced application that enables plate-based detection without requiring gels, electrophoresis, or transfer steps typically associated with Western blotting . This high-throughput approach uses two labeled antibodies (donor and acceptor fluorophores) that generate a FRET signal proportional to the concentration of phosphorylated protein .

How does phosphorylation at S386 affect IRF-3 structure and function?

Phosphorylation at S386 induces dramatic structural rearrangements in IRF-3. Crystallographic studies reveal that upon phosphorylation, the C-terminal tail containing the pLxIS motif undergoes a conformational transformation from a buried autoinhibitory configuration to an extended coil that mediates the formation of a domain-swapped dimer .

The phosphorylated S386 (represented by Glu386 in phosphomimetic mutants) interacts with Arg380, introducing a bend to the C-terminal tail that allows it to reach into the pLxIS motif-binding surface of a neighboring IRF-3 molecule . This structural change contributes to more than two-thirds of the total buried surface area (approximately 3,800 Ų) at the IRF-3 dimer interface . The hydrophobic residues Leu387, Val391, Leu393, and Ile395 extend into a long hydrophobic groove on the surface of IRF-3, while additional electrostatic interactions between Glu388 and Arg211 further stabilize the dimer .

How do different phosphorylation sites (S386 vs. S396) contribute to IRF-3 activation?

The relative contributions of S386 and S396 phosphorylation to IRF-3 activation have been the subject of extensive research:

Structural studies using the phosphomimetic IRF-3 S386/396E mutant revealed that:

• Unphosphorylated IRF-3 in complex with CBP is mostly monomeric and dimerizes weakly with an affinity of ~6 μM

• The S386/396E mutations increase binding affinity between IRF-3 molecules to 1.26 μM

• Complete phosphorylation of IRF-3 by TBK1 results in a stable dimer with a Kd of 167 nM

While S386 phosphorylation is crucial for initiating the conformational change required for dimerization, S396 phosphorylation provides additional stabilization by interacting with a positively charged cluster around Arg285 . The Lin group demonstrated that the IRF-3 mutant S386D/S396D bound to CBP forms a stable oligomer, suggesting that phosphorylation at both sites is essential for complete human IRF-3 activation .

What is the molecular mechanism underlying IRF-3 dimerization following S386 phosphorylation?

The precise molecular mechanism of IRF-3 dimerization following S386 phosphorylation has been elucidated through detailed structural studies:

• The phosphorylated S386 creates an interaction with Arg380, inducing a bend in the C-terminal tail

• This conformational change allows the exposure of the pLxIS motif, which can then interact with a neighboring IRF-3 molecule

• The IRF-3 dimer interface comprises:

  • A central region featuring hydrophobic interactions among Leu299, Leu300, and Trp358

  • Tail-mediated interactions that contribute approximately two-thirds of the total buried surface area

The dimerization process is further stabilized by additional phosphorylation events. For instance, phosphorylation site residue Thr253 is located at the IRF-3 dimer interface and may interact with Arg380 of a neighboring IRF-3 molecule upon phosphorylation . This explains why the binding affinity of fully phosphorylated IRF-3 (Kd = 167 nM) is significantly higher than that of the S386/396E phosphomimetic mutant (Kd = 1.26 μM) .

How conserved is the S386 phosphorylation mechanism across different IRF family members?

Sequence alignment analysis of IRF-3 and IRF-7 (another regulator of IFN-β induction) reveals that key residues mediating IRF-3 dimerization are conserved in IRF-7 . This suggests that a similar mechanism likely governs IRF-7 dimerization or IRF-3/7 heterodimerization.

What are the optimal sample preparation methods for detecting phospho-IRF3 (S386)?

Optimal sample preparation is crucial for reliable detection of phospho-IRF3 (S386):

For cell-based assays:

• The HTRF phospho-IRF3 (S386) assay employs a 2-plate protocol:

  • Culture cells in a 96-well plate before lysis

  • Transfer lysates to a 384-well low volume detection plate

  • Add phospho-IRF3 (S386) HTRF detection reagents

  • This protocol allows monitoring of cell viability and confluence

For Western blotting:

• Rapid sample preparation is essential to preserve phosphorylation status

• Use phosphatase inhibitors in lysis buffers

• The molecular weight of phospho-IRF3 is approximately 50-55 kDa

• For endogenous detection, viral infection or TBK1/IKKε activation is typically required

For immunofluorescence:

• Fixation method can significantly impact epitope accessibility

• Paraformaldehyde (4%) fixation followed by methanol permeabilization is often effective

• Include both positive controls (virally infected cells) and negative controls (phosphatase-treated samples)

How can researchers validate the specificity of phospho-IRF3 (S386) antibody staining?

Validation of antibody specificity is critical for accurate interpretation of results:

• Genetic controls: Compare staining between wild-type cells and IRF3-knockout cells or use S386A mutant-expressing cells

• Pharmacological controls: Treat samples with phosphatase to eliminate the phosphorylation signal

• Stimulation controls: Compare unstimulated cells with cells stimulated by viral infection or pathway activators

• Peptide competition: Pre-incubate the antibody with phosphorylated vs. non-phosphorylated peptides

• Multiple detection methods: Confirm results using alternative techniques (e.g., Western blot vs. immunofluorescence)

• Antibody validation: Consider using recombinant antibodies which provide superior lot-to-lot consistency

What are the recommended positive controls for phospho-IRF3 (S386) detection experiments?

Robust positive controls are essential for experimental validation:

• Viral infection: Cells infected with RNA viruses (e.g., Sendai virus, VSV) typically show strong IRF-3 phosphorylation

• TBK1/IKKε overexpression: Transient transfection with these kinases induces IRF-3 phosphorylation

• STING activation: Treatment with cGAMP or other STING agonists activates the IRF-3 pathway

• dsRNA mimetics: poly(I:C) treatment activates TLR3 and subsequent IRF-3 phosphorylation

• Phosphomimetic mutants: S386E can serve as a positive control in transfection experiments

• Recombinant phosphorylated protein: Can be generated using in vitro kinase assays with TBK1

What are common issues when detecting phospho-IRF3 (S386) in various experimental setups?

Researchers commonly encounter several challenges when working with phospho-IRF3 (S386):

• Rapid dephosphorylation: IRF-3 phosphorylation is dynamic and can be quickly reversed by cellular phosphatases

  • Solution: Maintain samples at 4°C and include phosphatase inhibitors in all buffers

• Low signal-to-noise ratio: Endogenous phosphorylation levels may be too low for detection

  • Solution: Optimize stimulation conditions or use signal amplification methods

• Antibody cross-reactivity: Some antibodies may recognize other phosphorylated epitopes

  • Solution: Validate specificity using S386A mutants or peptide competition assays

• Variable phosphorylation kinetics: The timing of S386 phosphorylation varies by cell type and stimulus

  • Solution: Perform time-course experiments to determine optimal time points

• Interference from other modifications: Multiple phosphorylation events occur on IRF-3

  • Solution: Use site-specific antibodies and consider the interplay between modifications

How can researchers resolve discrepancies between phospho-IRF3 (S386) detection and functional outcomes?

Discrepancies between phosphorylation detection and functional outcomes may arise for several reasons:

• Threshold effects: A certain threshold of S386 phosphorylation may be required for functional activation

  • Solution: Quantify phosphorylation levels relative to total IRF-3 and correlate with functional readouts

• Additional regulatory mechanisms: S386 phosphorylation is necessary but may not be sufficient for full activation

  • Solution: Assess additional modifications like S396 phosphorylation or IRF-3 dimerization

• Context-dependent requirements: Different cell types may have varying requirements for IRF-3 activation

  • Solution: Compare results across multiple cell types and experimental conditions

• Temporal dynamics: The duration of S386 phosphorylation may be more important than peak intensity

  • Solution: Perform detailed time-course analyses and area-under-curve calculations

• Subcellular localization: Phosphorylated IRF-3 must translocate to the nucleus to exert its function

  • Solution: Combine phospho-detection with localization studies (nuclear/cytoplasmic fractionation or imaging)

What factors might affect the phosphorylation state of IRF-3 at S386 in experimental settings?

Several experimental factors can influence IRF-3 phosphorylation status:

• Cell culture conditions: Confluency, serum starvation, and passage number can affect baseline pathway activation

• Spontaneous activation: Some cell lines (particularly cancer cells) may show constitutive pathway activation

• Mycoplasma contamination: Can trigger innate immune responses and IRF-3 activation

• Transfection reagents: May induce innate immune signaling and non-specific IRF-3 phosphorylation

• Sample handling: Mechanical stress during harvesting can activate stress pathways

• Cross-talk from other pathways: NF-κB activation or interferons present in the culture can influence results

• Antibody storage and handling: Freeze-thaw cycles or improper storage can reduce antibody specificity

Understanding these factors is essential for designing controlled experiments that yield reproducible and interpretable results when studying IRF-3 phosphorylation and activation.

How are phospho-IRF3 (S386) antibodies being applied in viral immunity research?

Phospho-IRF3 (S386) antibodies have become essential tools for investigating antiviral immune responses. The detection of S386 phosphorylation serves as a direct readout of pattern recognition receptor activation following viral infection. Recent advanced applications include:

• High-throughput screening of viral immune evasion factors that specifically target IRF-3 phosphorylation

• Real-time monitoring of IRF-3 activation kinetics in living cells using phospho-specific antibody-based biosensors

• Comparative analysis of IRF-3 activation profiles across different viral pathogens

• Evaluation of candidate antiviral compounds for their ability to modulate IRF-3 activation

The HTRF-based phospho-IRF3 (S386) detection platform has enabled increased throughput compared to traditional ELISA/Western blot approaches, facilitating larger-scale studies from basic research through preclinical drug discovery phases .

What structural insights have been gained from phospho-IRF3 (S386) research?

Structural studies utilizing phosphomimetic mutations and co-crystallization with binding partners have revealed remarkable insights into IRF-3 activation mechanisms:

The crystal structure of the IRF-3 S386/396E phosphomimetic mutant bound to CBP demonstrates that:

• The IRF-3 dimer interface can be subdivided into a smaller central region and tail-mediated interactions

• Hydrophobic interactions among Leu299, Leu300, and Trp358 form the core of the central dimer interface

• The C-terminal tail contributes more than two-thirds of the total buried surface area (~3,800 Ų)

• The phosphomimetic pLxIS motif interacts with a neighboring IRF-3 molecule similarly to how the phosphorylated pLxIS motif of STING interacts with IRF-3

These structural insights have profound implications for understanding the molecular basis of innate immune signaling and may inform the development of therapeutics targeting this pathway.